Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

Author: AngiolilloDominick J, BeckerRichard C, CannonChristopher P, DesaiBhaloo, EcobRosemary, EmanuelssonHakan, HustedSteen, PatilShankar B, StoreyRobert F, WallentinLars

Paper Details 
Original Abstract of the Article :
OBJECTIVES: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes. BACKGROUND: The PLATO study demonstrated superiority of ticagrelor over clopidogrel in the prevention...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.jacc.2010.03.100

データ提供:米国国立医学図書館(NLM)

Ticagrelor vs. Clopidogrel: Comparing Antiplatelet Effects in Acute Coronary Syndromes

This study compared the antiplatelet effects of ticagrelor and clopidogrel, two commonly used medications to prevent blood clots in patients with acute coronary syndromes (ACS). Using a randomized controlled trial, the study found that ticagrelor achieved greater suppression of platelet reactivity than clopidogrel, both in the first hours of treatment and during maintenance therapy. These findings suggest that ticagrelor may be a more effective antiplatelet agent for patients with ACS.

Ticagrelor: A Powerful Oasis in the Desert of Platelet Aggregation

This study examines the impact of two antiplatelet medications, ticagrelor and clopidogrel, on platelet aggregation in patients with acute coronary syndromes. The researchers found that ticagrelor achieved greater suppression of platelet aggregation than clopidogrel, providing a more effective solution for preventing blood clots in this high-risk population. The study highlights the importance of choosing the most effective antiplatelet agent for individual patients.

Minimizing the Risk of Blood Clots

This study emphasizes the importance of careful medication selection to minimize the risk of blood clots in patients with acute coronary syndromes. The findings suggest that ticagrelor may offer a more powerful and effective solution for preventing these potentially life-threatening complications.

Dr. Camel's Conclusion

This study provides valuable insights into the antiplatelet effects of ticagrelor and clopidogrel in patients with acute coronary syndromes. The results suggest that ticagrelor may be a more effective option for preventing blood clots and reducing the risk of ischemic events. However, it is crucial to consult with a healthcare professional to determine the best treatment plan for individual patients.

Date :
  1. Date Completed 2010-11-02
  2. Date Revised 2023-08-08
Further Info :

Pubmed ID

20832963

DOI: Digital Object Identifier

10.1016/j.jacc.2010.03.100

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.